Developing Blood Tests to Detect and Monitor Pancreatic Cancer Early and Track Treatment Response

What this Trial Is About

Researchers are developing a minimally invasive blood test to diagnose pancreatic cancer at early stages and to monitor how patients respond to treatment. This observational study includes patients with various pancreatic conditions and healthy controls, aiming to improve early detection and treatment tracking for pancreatic cancer. The study is sponsored by Memorial Sloan Kettering Cancer Center. Participants are grouped into several cohorts based on their pancreatic condition, including advanced pancreatic cancer, operable pancreatic cancer, acute and chronic benign pancreatic diseases, pancreatic cysts, and healthy controls. Blood and sweat samples will be collected, and tissue samples may be obtained through planned biopsies or surgeries. Sampling schedules vary by cohort, with some involving samples before treatment or surgery and others involving repeated samples every 6 to 12 months according to institutional guidelines. During the study, participants will provide blood and possibly tissue or cyst fluid samples for biomarker analysis. Researchers will assess changes in these biomarkers over four years to determine the tests sensitivity and specificity for early pancreatic cancer diagnosis. Participation involves periodic sample collections and clinical evaluations, with safety monitored throughout. The study is open to adults aged 18 and older and includes healthy volunteers as well.

A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma